EuroBiotech: More Articles of Note


> Cinclus Pharma secured funding to support its preparations for a phase 2 trial of a potassium competitive acid blocker in erosive gastroesophageal reflux disease. Statement 

> Mereo BioPharma completed its reverse merger with OncoMed Pharmaceuticals and began trading on Nasdaq. The developments extend Mereo’s cash runway out to the middle of next year. Release I More

> The FDA granted orphan drug status to Autolus Therapeutics’ CD19-CD22 cell therapy AUTO3 in the treatment of acute lymphoblastic leukemia. Statement 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Marinomed Biotech posted top-line data from a phase 3 clinical trial of allergic rhinitis nasal spray Budesolv. The trial found Budesolv had comparable effects to another budesonide product but at a lower dose. Release 

> Cytura Therapeutics raised seed funding to develop drugs targeting genomic instability in cancer.  A syndicate led by Thuja Capital Healthcare put up the money. Statement 

> Oxurion completed enrollment in a phase 1 trial of plasma kallikrein inhibitor THR-149 ahead of schedule. The milestone positions Oxurion to share initial data on the diabetic macular edema prospect early in the third quarter. Release 

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.